

Ellipsys Vascular Access System, Medical 318

Table of Content

[Purpose](#)
[Description & Definitions](#)
[Criteria](#)
[Coding](#)
[Document History](#)
[References](#)
[Special Notes](#)
[Keywords](#)

Effective Date 8/2019
Next Review Date 1/2025
Coverage Policy Medical 318
Version 5

Member-specific benefits take precedence over medical policy and benefits may vary across plans. Refer to the individual's benefit plan for details [*](#).

Purpose:

This policy addresses the medical necessity of Ellipsys Vascular Access System.

Description & Definitions:

The Ellipsys vascular access system uses a minimally invasive device to join the artery and vein together to create an Arteriovenous Fistula (AVF) guided by ultrasound and thermal energy.

Criteria:

Ellipsys Vascular Access System is considered not medically necessary for any indication.

Coding:

Medically necessary with criteria:

| Coding | Description |
|--------|-------------|
| | None |

Considered Not Medically Necessary:

| Coding | Description |
|--------|---|
| 36836 | Percutaneous arteriovenous fistula creation, upper extremity, single access of both the peripheral artery and peripheral vein, including fistula maturation procedures (eg, transluminal balloon angioplasty, coil embolization) when performed, including all vascular access, imaging guidance and radiologic supervision and interpretation |
| 36837 | Percutaneous arteriovenous fistula creation, upper extremity, separate access sites of the peripheral artery and peripheral vein, including fistula maturation procedures (eg, transluminal balloon angioplasty, coil embolization) when performed, including all vascular access, imaging guidance and radiologic supervision and interpretation |

| | |
|-------|--------------------------------------|
| 37799 | Unlisted procedure, vascular surgery |
|-------|--------------------------------------|

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2020: January

Reviewed Dates:

- 2024: January
- 2023: January
- 2022: February
- 2021: February
- 2020: April

Effective Date:

- August 2019

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2024). Retrieved Jan 2024, from MCG 27th Edition: <https://careweb.careguidelines.com/ed27/index.html>

Code of Federal Regulations Title 21 CFR Sec. 870.1252 Percutaneous catheter for creation of an arteriovenous fistula for hemodialysis access. (2023, Oct 17). Retrieved Jan 2024, from FDA: <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=870.1252>

National Coverage Determination (NCD) Percutaneous Transluminal Angioplasty (PTA) 20.7. (2013, Jan). Retrieved Jan 2024, from CMS - NCD: <https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?ncdid=201&ncdver=10&bc=0>

Percutaneous arteriovenous fistula creation. (2023). Retrieved Jan 2024, from HAYES: <https://evidence.hayesinc.com/search?q=%257B%2522text%2522:%2522Percutaneous%2520arteriovenous%2520fistula%2520creation%2522,%2522title%2522:null,%2522termsource%2522:%2522searchbar%2522,%2522page%2522:%2522page%2522:0,%2522size%2522:50%252D,%2522typ>

Procedure Fee Files & CPT Codes. (2023). Retrieved Jan 2024, from Department of Medical Assistance Services: <https://www.dmas.virginia.gov/for-providers/rates-and-rate-setting/procedure-fee-files-cpt-codes/> & <https://www.dmas.virginia.gov/for-providers/cardinal-care-transition/>

Technical aspects of percutaneous endovascular arteriovenous fistula creation with the Ellipsys® Vascular Access System. (2023, Jan 17). Retrieved Jan 2024, from Langenbeck's Archives of Surgery: NIH: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931805/pdf/423_2023_Article_2812.pdf

The Ellipsys® Vascular Access System. (2024). Retrieved Jan 2024, from AVENU MEDICAL: <https://avenumedical.com/ellipsys/>

KDOQI Clinical Practice Guideline for Vascular Access (2020, Apr). Retrieved Jan 2024, from American Journal of Kidney Diseases <https://www.ajkd.org/action/showPdf?pii=S0272-6386%2819%2931137-0>

Special Notes: *

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment, and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving, and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

Services mean both medical and behavioral health (mental health) services and supplies unless We specifically tell You otherwise. We do not cover any services that are not listed in the Covered Services section unless required to be covered under state or federal laws and regulations. We do not cover any services that are not Medically Necessary. We sometimes give examples of specific services that are not covered but that does not mean that other similar services are covered. Some services are covered only if We authorize them. When We say You or Your We mean You and any of Your family members covered under the Plan. Call Member Services if You have questions.

Keywords:

SHP Ellipsys Vascular Access System, SHP Medical 318, hemodialysis, arteriovenous fistula, end-stage renal disease, EndoAVF, Endovascular creation of arteriovenous fistula, Percutaneous Arteriovenous Fistula (pAVF) for Hemodialysis, Ellipsys Vascular Access System (Ellipsys System), Crossing Needle, EndoAVF, Percutaneous Arteriovenous Fistula (pAVF) for Hemodialysis, endo-AV fistulas, WavelinQ System